Once-weekly semaglutide improved fatty liver disease in 70% of type 2 diabetes patients over 52 weeks, with preferential loss of visceral fat over muscle mass.
70% improvedSeven in ten type 2 diabetes patients saw their fatty liver disease improve by at least one severity grade after 52 weeks of semaglutide
What the researchers found
After 52 weeks of once-weekly subcutaneous semaglutide added to metformin, 70% of type 2 diabetes patients with fatty liver disease showed improvement — reducing their liver steatosis by at least one ultrasound-assessed grade. The treatment produced significant decreases in body weight, insulin resistance, liver enzymes, and laboratory markers of hepatic fat accumulation.
Notably, semaglutide preferentially reduced fat mass and visceral adipose tissue (the dangerous belly fat surrounding organs) more than skeletal muscle or lean mass. Ultrasound-measured visceral fat thickness and a 12-point steatosis severity score both declined progressively from 3 months through the full 12-month treatment period.
Why it matters
Nonalcoholic fatty liver disease affects roughly 70% of type 2 diabetes patients and can progress to cirrhosis and liver cancer. Until recently, there were no approved drugs specifically for NAFLD — weight loss was the only reliable treatment. This real-world study shows that semaglutide addresses both diabetes and fatty liver simultaneously, with measurable liver improvements in the majority of patients over one year. It adds to growing evidence that GLP-1 agonists may become a cornerstone treatment for metabolic liver disease.
The numbers in context
n=48 · 52-week treatment · 70% showed steatosis improvement by ≥1 grade · Significant decreases in VAT, liver enzymes, insulin resistance · Preferential fat loss over muscle loss
How the study worked
Forty-eight type 2 diabetes patients with NAFLD received once-weekly subcutaneous semaglutide alongside their existing metformin. They were assessed at baseline, 3 months, 6 months, and 12 months. At each visit, body composition was measured using bio-impedance analysis, and liver fat was evaluated by ultrasound imaging with a semiquantitative 12-point steatosis scoring system. Blood tests tracked glucose control, liver enzymes, insulin resistance markers, and calculated indices of hepatic steatosis.
Who was studied
48 adults with type 2 diabetes and nonalcoholic fatty liver disease
What this study cannot tell us
This was a single-center, uncontrolled prospective study with only 48 patients — there was no placebo or comparison group, so improvements can't be definitively attributed to semaglutide alone versus lifestyle changes or natural progression. The use of ultrasound rather than MRI for liver fat assessment is less precise. As a real-world study, treatment adherence and concurrent lifestyle modifications weren't strictly controlled.
How to read the evidence
This is a prospective real-world study with consistent follow-up over 12 months and multiple objective outcome measures. However, the lack of a control group, small sample size (n=48), and single-center design limit the strength of causal conclusions.
When this study was published
Published in 2022, this study is recent and relevant. It aligns with growing evidence from larger trials (like the phase 2 semaglutide NASH trial) supporting GLP-1 agonists for metabolic liver disease.
The bigger picture
NAFLD is rapidly becoming one of the leading causes of liver transplants worldwide, driven by the obesity and diabetes epidemics. While several drugs are being developed specifically for fatty liver disease, GLP-1 agonists like semaglutide are emerging as a treatment that hits multiple metabolic targets at once — blood sugar, body weight, visceral fat, and liver health. Real-world studies like this one complement the larger clinical trials and show that these benefits translate to everyday clinical practice.
Questions still open
- Would semaglutide's liver benefits persist if the drug were stopped, or would fatty liver return with weight regain?
- How does semaglutide compare to dedicated NAFLD treatments like resmetirom (the first FDA-approved drug for metabolic liver disease)?
- Could higher doses of semaglutide produce even greater liver improvements, or is there a ceiling effect?
Common questions
Can semaglutide treat fatty liver disease, not just diabetes?
Does semaglutide cause muscle loss along with fat loss?
Read the original research
Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.
Nutrients, 14(21)
Citation
Volpe, Sara; Lisco, Giuseppe; Fanelli, Margherita; Racaniello, Davide; Colaianni, Valentina; Triggiani, Domenico; Donghia, Rossella; Crudele, Lucilla; Rinaldi, Roberta; Sabbà, Carlo; Triggiani, Vincenzo; De Pergola, Giovanni; Piazzolla, Giuseppina. (2022). Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.. Nutrients, 14(21). https://doi.org/10.3390/nu14214673